Drug resistance in antiretroviral-naive children newly diagnosed with HIV-1 in Manaus, Amazonas.
PMID: 28333295
2017
The Journal of antimicrobial chemotherapy
Abstract: The most common DRM was E138A (8.5%).
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
PMID: 28369593
2017
The Journal of antimicrobial chemotherapy
Abstract: Only one secondary mutation (E138A) was found in one of the 20 raltegravir-naive HIV-2 patients.
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.
Abstract: The most frequently emerging etravirine resistance-associated mutations in virologic failures were Y181C, E138A, and M230L.
Result: The most frequently emerging etravirine RAMs (developing in >=5 VFs) were Y181C (18/49), E138A (5/49), and M230L (5/49).
Discussion: The most frequently emerging etravirine RAMs, Y181C, E138A, and M230L (>=5 VFs) have also been observed previously in patients with VF in etravirine trials, as has the only other NNRTI RAM that emerged in >=5 VFs, H221Y.
The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012-2014.
Result: 31 specific DRMs were identified from 27 samples with DRMs distributing as: 1) 74.2% (23/31) DRMs were on nonnucleoside reverse transcriptase inhibitors (NNRTIs) as: V179E/D (n = 16), K238N (n = 2), E138A/G (n = 4) and G190E (n = 1).
Result: For example, 16 of 27 donors showed PLLR (or above) to NNRTI due to V179D/E mutations; three donors with mutations of E138A were found to have PLLR to etravirine (ETR) and low-level resistance (LLR) to rilpivirine (RPV); specimen CQ12003214 was identified to have PLLR to five PIs and intermediate resistance (IR) to nelfinavir (NFV) caused by
Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection.
Result: 1b, c), rilpivirine resistance-associated mutations E138A followed by E138G and E138K accounted for more than 95% of reverse transcriptase codon 138 variants across HIV-1 subtypes A-G and CRFs 01_AE and 02_AG in the Stanford database (Supplemental Figure 1, http://links.lww.com/QAD/B122).
Result: Although relative enrichment of E138A in HIV-1 subtype C compared with subtype B has previously been reported, reverse transcriptase-E138X distribution is incompletely characterized in other major HIV-1 subtypes though the data in.
Result: The most common variants at this position, comprising 97.6% of all those observed, were E138A, followed by E138G and PMID: 28688977
2017
Infection, genetics and evolution
Abstract: For subtype B, 68.1% (139 out of 204) of resistant strains (E138A, K103N, E138Q V179D) belonged to clusters.
Abstract: The majority of subtype A sequences (89.7%; 245 out of 273) with the dominant NNRTI resistance mutations (E138A, K103N, E138Q, V179D) were found to belong to monophyletic clusters suggesting regional dispersal.
Abstract: The most frequently observed NNRTI resistant mutations were E138A (7.7%), E138Q (4.0%), K103N (2.3%) and V179D (1.3%).
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors.
PMID: 28732792
2017
Journal of global antimicrobial resistance
Abstract: No significant differences were observed between the prevalence rates of TDRMs involving one or more drugs, except for the presence of E138A quite only in patients with B subtype and other NNRTI in subjects with non-B infection.
High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
Result: E138A/K/Q, a mutation related to the NNRTIs etravirine (ETR) and rilpivirine (RPV) was found in 8.6% of subjects, although these drugs are not currently available and not part of the standard treatment regimen in South Africa.
Result: Excluding E138A/K/Q among NNRTI mutations reduced the NNRTI resistance prevalence from 65.2 to 62.5%.
Discussion: In fact, in the Stanford Drug Resistance database, subtype C strains from drug exposed patients have a higher prevalence of the E138A/K/Q mutation compared to other group M strains (8-9.5% vs.
Discussion: Similarly, we speculate that the occurrence of the E138A/K/Q mutation could be due to the codon usage of subtype C
Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014.
PMID: 28799325
2017
Journal of the International AIDS Society
Result: Mainly, E138A predicted to mostly affect rilpivirine resistance, was identified in three patients (infected with subtype A, AG and C) by both sequencing platforms (Figure 1).
Discussion: Here, six of the patients harboured E138 substitutions, three of whom had E138A.
Discussion: However, studies do monitor this location, especially the E138A substitution inhibiting rilpivirine, whose prevalence has been shown to vary by geographical region and HIV-1 subtype; in Europe, it was identified in 3.1% of the recently infected patients.
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Result: Specifically, those participants with A62V, V90I, K103N, or E138A/G/K/Q/R in RT, or M46I/L or L33F in PR, had HIV-1 RNA <50 copies/mL at Week 48 after treatment with EVG/COBI/FTC/TDF or ATV+RTV+FTC/TDF at proportions similar to the overall treated population (Table 5).
Result: The most common NNRTI-associated substitutions were V90I, E138A, and K103N.
Result: The most common pre-existing NRTI- and NNRTI-associated substitutions were
HIV mutation literature information.
PMID: 
2017
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT